The abstract focuses exclusively on amyloid plaque reduction, leaving unknown whether this pathway addresses tau tangles, neuroinflammation, or synaptic loss. Since AD is multifactorial, understanding the full therapeutic scope is essential for clinical translation.
Gap type: open_question
Source paper: Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystatin-c activation of TREM2. (2026, Cell, PMID:41576952)
Cystatin C binds tau through its cystatin-like domain, sequestering monomeric tau and preventing β-sheet aggregation. This hypothesis has the weakest mechanistic foundation: cystatin C is secreted (extracellular) while tau is predominantly intracellular. The 2005 Co-IP has not been independently replicated in 20+ years. At physiologically relevant concentrations (10-50 nM CSF), any inhibitory effect may be negligible.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Glymphatic Dysfunction Sleep Disruption and AQP4 Depolarization"]
B["Impaired ISF-CSF Exchange Perivascular Clearance Failure"]
C["Tau Accumulation MAPT-Encoded Tau Aggregation"]
D["Tau Seeding and Spreading Prion-like Trans-neuronal Propagation"]
E["Neurodegeneration Synaptic Loss and Cognitive Decline"]
F["Glymphatic Enhancement Sleep Optimization or Norepinephrine Reduction"]
A --> B
B --> C
C --> D
D --> E
F -.->|"restores"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784
Median TPM across 13 brain regions for CST3/MAPT interaction from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
10 citations10 with PMIDValidation: 0%7 supporting / 3 opposing
✓For(7)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
8
2
MECH 8CLIN 0GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Cystatin C co-immunoprecipitates with tau in human…
Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration By rel…▼
Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration By release of loop anchoring through mutation of his110.
Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal b…▼
Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal binding region as a selectivity-conferring residue in the inhibition of mammalian cysteine peptidases.
Importance of the evolutionarily conserved glycine residue in the N-terminal region of human cystatin C (Gly-1…▼
Importance of the evolutionarily conserved glycine residue in the N-terminal region of human cystatin C (Gly-11) for cysteine endopeptidase inhibition.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Hypothesis 1: TREM2-Dependent Microglial Phagocytosis of Tau Seeds
Title: Cystatin-C-activated TREM2 microglia reduce tau pathology through enhanced phagocytosis of extracellular tau seeds
Mechanism: TREM2 activation by cystatin C promotes a disease-associated microglia (DAM) phenotype with enhanced phagocytic capacity. Activated microglia may ingest and clear extracellular tau oligomers and seeds, preventing template-dependent propagation of tau tangles.
Target: TREM2 signaling axis (Syk → PLCγ2),
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Hypotheses: Cancer-Cystatin-C-TREM2 Pathway Beyond Amyloid
Preliminary Methodological Concerns
Before evaluating individual hypotheses, several systemic issues constrain confidence across all seven proposals:
1. Causal vs. Correlative Ambiguity The source paper establishes a correlation between peripheral cancer, elevated cystatin C, and reduced amyloid burden. All seven hypotheses require demonstrating that cystatin C is both necessary and sufficient for non-amyloid effects—a causation that has not been established even for the amyloid phenotype.
**2. Blood
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
The key feasibility filter is the source paper itself. In the February 5, 2026 `Cell` paper, Li et al. report that peripheral cancer/CSPs reduced amyloid in `5xFAD` and `APP/PS1`, but “did not affect tau protein misfolding in the `rTg4510` mice,” which sharply limits any claim of a broad anti-tau effect beyond amyloid-linked contexts. Separately, the March 5, 2026 phase 2 `AL002` TREM2 agonist trial showed CNS target engagement but missed its clinical primary endpoint in early AD, so the translational bar for any TREM2-based program is now much higher. Sources: `Cell` paper abstract/PDF and `N
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Anti-inflammatory microglial reprogramming via cystatin-C/TREM2 axis","description":"Systemic tumors secrete cystatin C which crosses the BBB via LRP1 and engages TREM2 on microglia, shifting neuroinflammatory profile from pro-inflammatory (IL-1β, TNF-α, IL-6) to anti-inflammatory/regulatory (IL-10, TGF-β). This represents the most druggable pharmacology story, though the field's first major TREM2 agonist phase 2 (AL002) missed its clinical primary endpoint despite biomarker engagement. Clinical translation requires biomarker-enriched populations and likely comb
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF recombinant human CST3 is added at 10-50 nM (physiological CSF concentration) to in vitro Thioflavin-T tau aggregation assays with recombinant MAPT (2N4R), THEN ThT fluorescence will be reduced by >30% compared to vehicle control within 48 hours.
pendingconf: 0.10
Expected outcome: Significant reduction in tau fibril formation with ThT fluorescence decreasing by >30% relative to control
Falsified by: No significant reduction in ThT fluorescence (<20% change) or ThT signal unchanged/increased after CST3 treatment
Method: Purified full-length human MAPT (2N4R) at 10 μM induced to aggregate with arachidonic acid; recombinant human CST3 (rCST3) added at 10-50 nM; ThT fluorescence measured at 0, 24, and 48 hours; negative-stain EM confirmation of fibrils
IF full-length human CST3 is overexpressed intracellularly at 3-fold above endogenous levels in HEK293T cells engineered to aggregate tau (FRET-based biosensor line), THEN tau aggregate burden will decrease by >25% within 72 hours post-transfection.
pendingconf: 0.05
Expected outcome: FRET signal reduction of >25% indicating decreased tau aggregation, with cell viability unchanged
Falsified by: FRET signal unchanged or increased (<10% change), or filter trap assay shows no reduction in insoluble tau; no change in phosphorylation state (AT8, AT180)
Method: HEK293T FRET biosensor cells (expressing tau RD-CFP/YFP) transfected with CST3-pcDNA3.1 or empty vector; FRET measured by live-cell imaging at 24, 48, 72h; filter trap assay for insoluble tau; Western blot for phospho-tau (AT8, AT180); viability assay (WST-8) to control for toxicity